Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
DURHAM, N.C., Oct. 25, 2016 -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its pulmonary research and development efforts will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida, October 27 through 29, 2016.
The accepted abstract is titled “PULMONARY AEROSOL DEPOSITION IN CHILDREN WITH CYSTIC FIBROSIS FOLLOWING TRANSNASAL DELIVERY OF HYPERTONIC SALINE” and is poster number 459. The poster will include deposition, safety, and tolerability data from the trial of a novel transnasal delivery device to deliver hypertonic saline to the lungs of children with Cystic Fibrosis. It will be presented on Thursday, October 27th between 11:15 am and 1:45 pm during the formal poster session.
The transnasal delivery device used in the study was developed and tested with the support of the Cystic Fibrosis Foundation.
About Parion Sciences
Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at www.Parion.com.
Contact: Joe Schachle Chief Operating Officer (919)313-1194 [email protected]
